全文获取类型
收费全文 | 2055320篇 |
免费 | 145595篇 |
国内免费 | 5601篇 |
专业分类
耳鼻咽喉 | 28231篇 |
儿科学 | 63916篇 |
妇产科学 | 57072篇 |
基础医学 | 299221篇 |
口腔科学 | 57691篇 |
临床医学 | 192362篇 |
内科学 | 389807篇 |
皮肤病学 | 40895篇 |
神经病学 | 169406篇 |
特种医学 | 76993篇 |
外国民族医学 | 533篇 |
外科学 | 296160篇 |
综合类 | 49598篇 |
现状与发展 | 3篇 |
一般理论 | 701篇 |
预防医学 | 170575篇 |
眼科学 | 46642篇 |
药学 | 151804篇 |
51篇 | |
中国医学 | 4475篇 |
肿瘤学 | 110380篇 |
出版年
2018年 | 22183篇 |
2017年 | 16931篇 |
2016年 | 18464篇 |
2015年 | 21360篇 |
2014年 | 29876篇 |
2013年 | 45890篇 |
2012年 | 62646篇 |
2011年 | 66285篇 |
2010年 | 38616篇 |
2009年 | 35746篇 |
2008年 | 61236篇 |
2007年 | 65234篇 |
2006年 | 65246篇 |
2005年 | 63607篇 |
2004年 | 61373篇 |
2003年 | 58621篇 |
2002年 | 56687篇 |
2001年 | 87894篇 |
2000年 | 90029篇 |
1999年 | 76002篇 |
1998年 | 22308篇 |
1997年 | 20330篇 |
1996年 | 19954篇 |
1995年 | 18945篇 |
1994年 | 17930篇 |
1993年 | 16781篇 |
1992年 | 62095篇 |
1991年 | 60773篇 |
1990年 | 59296篇 |
1989年 | 56574篇 |
1988年 | 52819篇 |
1987年 | 51772篇 |
1986年 | 49313篇 |
1985年 | 47395篇 |
1984年 | 36146篇 |
1983年 | 30901篇 |
1982年 | 19032篇 |
1981年 | 17144篇 |
1979年 | 34599篇 |
1978年 | 24791篇 |
1977年 | 20604篇 |
1976年 | 19742篇 |
1975年 | 20669篇 |
1974年 | 25484篇 |
1973年 | 24744篇 |
1972年 | 23213篇 |
1971年 | 21616篇 |
1970年 | 20228篇 |
1969年 | 19101篇 |
1968年 | 17637篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
Cost‐Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States 下载免费PDF全文
82.
Lisa Daniels Rachael W. Taylor Sheila M. Williams Rosalind S. Gibson Samir Samman Benjamin J. Wheeler Barry J. Taylor Elizabeth A. Fleming Nicola K. Hartley Anne-Louise M. Heath 《Journal of the Academy of Nutrition and Dietetics》2018,118(6):1006-1016.e1
Background
Little is known about zinc intakes and status during complementary feeding. This is particularly true for baby-led approaches, which encourage infants to feed themselves from the start of complementary feeding, although self-feeding may restrict the intake of zinc-rich foods.Objective
To determine the zinc intakes, sources, and biochemical zinc status of infants following Baby-Led Introduction to SolidS (BLISS), a modified version of Baby-Led Weaning (BLW), compared with traditional spoon-feeding.Design
Secondary analysis of the BLISS randomized controlled trial.Participants/setting
Between 2012 and 2014, 206 community-based participants from Dunedin, New Zealand were randomized to a Control or BLISS group.Intervention
BLISS participants received eight study visits (antenatal to 9 months) providing education and support regarding BLISS (ie, infant self-feeding from 6 months with modifications to address concerns about iron, choking, and growth).Main outcome measures
Dietary zinc intakes at 7 and 12 months (weighed 3-day diet records) and zinc status at 12 months (plasma zinc concentration).Statistical analyses performed
Regression analyses were used to investigate differences in dietary intakes and zinc status by group, adjusted for maternal education and parity and infant age and sex.Results
There were no significant differences in zinc intakes between BLISS and Control infants at 7 (median: 3.5 vs 3.5 mg/day; P=0.42) or 12 (4.4 vs 4.4 mg/day; P=0.86) months. Complementary food groups contributing the most zinc at 7 months were “vegetables” for Control infants, and “breads and cereals” for BLISS infants, then “dairy” for both groups at 12 months. There was no significant difference in mean±standard deviation plasma zinc concentration between the Control (62.8±9.8 μg/dL [9.6±1.5 μmol/L]) and BLISS (62.8±10.5 μg/dL [9.6±1.6 μmol/L]) groups (P=0.75).Conclusions
BLISS infants achieved similar zinc intake and status to Control infants. However, the BLISS intervention was modified to increase iron intake, which may have improved zinc intake, so these results should not be generalized to infants following unmodified BLW. 相似文献83.
Laura A. Smith Ciara H. O’Flanagan Laura W. Bowers Emma H. Allott Stephen D. Hursting 《Journal of the Academy of Nutrition and Dietetics》2018,118(4):652-667
Prevalence of obesity, an established risk factor for many cancers, has increased dramatically over the past 50 years in the United States and across the globe. Relative to normoweight cancer patients, obese cancer patients often have poorer prognoses, resistance to chemotherapies, and are more likely to develop distant metastases. Recent progress on elucidating the mechanisms underlying the obesity?cancer connection suggests that obesity exerts pleomorphic effects on pathways related to tumor development and progression and, thus, there are multiple opportunities for primary prevention and treatment of obesity-related cancers. Obesity-associated alterations, including systemic metabolism, adipose inflammation, growth factor signaling, and angiogenesis, are emerging as primary drivers of obesity-associated cancer development and progression. These obesity-associated host factors interact with the intrinsic molecular characteristics of cancer cells, facilitating several of the hallmarks of cancer. Each is considered in the context of potential preventive and therapeutic strategies to reduce the burden of obesity-related cancers. In addition, this review focuses on emerging mechanisms behind the obesity?cancer link, as well as relevant dietary interventions, including calorie restriction, intermittent fasting, low-fat diet, and ketogenic diet, that are being implemented in preclinical and clinical trials, with the ultimate goal of reducing incidence and progression of obesity-related cancers. 相似文献
84.
85.
Camila L.P. Oliveira Stephanie Mattingly Ralf Schirrmacher Michael B. Sawyer Eugene J. Fine Carla M. Prado 《Journal of the Academy of Nutrition and Dietetics》2018,118(4):668-688
The predominant use of glucose anaerobically by cancer cells (Warburg effect) may be the most important characteristic the majority of these cells have in common and, therefore, a potential metabolic pathway to be targeted during cancer treatment. Because this effect relates to fuel oxidation, dietary manipulation has been hypothesized as an important strategy during cancer treatment. As such, the concept of a ketogenic diet (KD) in cancer emerged as a metabolic therapy (ie, targeting cancer cell metabolism) rather than a dietary approach. The therapeutic mechanisms of action of this high-fat, moderate-to-low protein, and very-low-carbohydrate diet may potentially influence cancer treatment and prognosis. Considering the lack of a dietetics-focused narrative review on this topic, we compiled the evidence related to the use of this diet in humans with diverse cancer types and stages, also focusing on the nutrition and health perspective. The use of KD in cancer shows potentially promising, but inconsistent, results. The limited number of studies and differences in study design and characteristics contribute to overall poor quality evidence, limiting the ability to draw evidence-based conclusions. However, the potential positive influences a KD may have on cancer treatment justify the need for well-designed clinical trials to better elucidate the mechanisms by which this dietary approach affects nutritional status, cancer prognosis, and overall health. The role of registered dietitian nutritionists is demonstrated to be crucial in planning and implementing KD protocols in oncology research settings, while also ensuring patients’ adherence and optimal nutritional status. 相似文献
86.
Conrad M. Tobert Sarah L. Mott Kenneth G. Nepple 《Journal of the Academy of Nutrition and Dietetics》2018,118(1):125-131
Background
Malnutrition is a significant problem for hospitalized patients. However, the true prevalence of reported malnutrition diagnosis in real-world clinical practice is largely unknown. Using a large collaborative multi-institutional database, the rate of malnutrition diagnosis was assessed and used to assess institutional variables associated with higher rates of malnutrition diagnosis.Objective
The aim of this study was to define the prevalence of malnutrition diagnosis reported among inpatient hospitalizations.Design
The University Health System Consortium (Vizient) database was retrospectively reviewed for reported rates of malnutrition diagnosis.Participants/setting
All adult inpatient hospitalization at 105 member institutions during fiscal years 2014 and 2015 were evaluated.Main outcome measures
Malnutrition diagnosis based on the presence of an International Classification of Diseases-Ninth Revision diagnosis code.Statistical analysis
Hospital volume and publicly available hospital rankings and patient satisfaction scores were obtained. Multiple regression analysis was performed to assess the association between these variables and reported rates of malnutrition.Results
A total of 5,896,792 hospitalizations were identified from 105 institutions during the 2-year period. It was found that 292,754 patients (5.0%) had a malnutrition diagnosis during their hospital stay. By institution, median rate of malnutrition diagnosis during hospitalization was 4.0%, whereas the rate of severe malnutrition diagnosis was 0.9%. There was a statistically significant increase in malnutrition diagnosis from 4.0% to 4.9% between 2014 and 2015 (P<0.01). Institutional factors associated with increased diagnosis of malnutrition were higher hospital volume, hospital ranking, and patient satisfaction scores (P<0.01).Conclusions
Missing a malnutrition diagnosis appears to be a universal issue because the rate of malnutrition diagnosis was consistently low across academic medical centers. Institutional variables were associated with the prevalence of malnutrition diagnosis, which suggests that institutional culture influences malnutrition diagnosis. Quality improvement efforts aimed at improved structure and process appear to be needed to improve the identification of malnutrition. 相似文献87.
Qian Zhang Yunmei Song Stephen W. Page Sanjay Garg 《Journal of pharmaceutical sciences》2018,107(2):587-594
The transdermal delivery of 2 fluorescent probes with similar molecular weight but different lipophilicity, into and through the skin from 2 commercially available transdermal bases, pluronic lecithin organogel, and Lipoderm® has been evaluated. First, in vitro penetration of fluorescein sodium and fluorescein (free acid) through porcine skin was evaluated. Retention and depth distribution profiles in skin were obtained by tape stripping and then followed by optical sectioning using multiphoton microscopy. The results showed that Lipoderm® led to an enhanced penetration of the hydrophilic compound, fluorescein sodium. For the lipophilic compound fluorescein (free acid), Lipoderm® performed similar to pluronic lecithin organogel base, where minimal drug was detected in either receptor phase. The skin retention and depth distribution results also showed that the hydrophilic fluorescein sodium had high skin retention with Lipoderm®, whereas fluorescein (free acid) had very low penetration and retention with increasing skin depth. Moreover, optical sectioning by multiphoton microscopy revealed an uneven distribution of probes across the skin in the x-y plane for both transdermal bases. This work showed that a hydrophilic compound has significantly increased skin penetration and retention when formulated with Lipoderm®, and the skin retention of the probe was the main determinant of its skin flux. 相似文献
88.
89.
Bo Feng Angela C. Doran Li Di Mark A. West Sarah M. Osgood Jessica Y. Mancuso Christopher L. Shaffer Larry Tremaine Jennifer Liras 《Journal of pharmaceutical sciences》2018,107(8):2225-2235
Four P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) substrates with human cerebrospinal fluid (CSF) concentrations and preclinical neuropharmacokinetics were used to assess in vitro–in vivo extrapolation of brain penetration in preclinical species and the ability to predict human brain penetration. Unbound brain (Cb,u), unbound plasma (Cp,u), and CSF compound concentrations (CCSF) were measured in rats and nonhuman primates (NHPs), and the unbound partition coefficients (Cb,u/Cp,u and CCSF/Cp,u) were used to assess brain penetration. The results indicated that for P-gp and BCRP dual substrates, brain penetration was severally impaired in all species. In comparison, for P-gp substrates that are weak or non-BCRP substrates, improved brain penetration was observed in NHPs and humans than in rats. Overall, NHP appears to be more predictive of human brain penetration for P-gp substrates with weak or no interaction with BCRP than rat. Although CCSF does not quantitatively correspond to Cb,u for efflux transporter substrates, it is mostly within 3-fold higher of Cb,u in rat and NHP, suggesting that CCSF can be used as a surrogate for Cb,u. Taken together, a holistic approach including both in vitro transporter and in vivo neuropharmacokinetics data enables a better estimation of human brain penetration of P-gp/BCRP substrates. 相似文献
90.
Verônica M. Couto Maria J. Prieto Daniela E. Igartúa Daniela A. Feas Lígia N.M. Ribeiro Camila M.G. Silva Simone R. Castro Viviane A. Guilherme Darlene D. Dantzger Daisy Machado Silvia del V. Alonso Eneida de Paula 《Journal of pharmaceutical sciences》2018,107(9):2411-2419
Administration of local anesthetics is one of the most effective pain control techniques for postoperative analgesia. However, anesthetic agents easily diffuse into the injection site, limiting the time of anesthesia. One approach to prolong analgesia is to entrap local anesthetic agents in nanostructured carriers (e.g., liposomes). Here, we report that using an ammonium sulphate gradient was the best strategy to improve the encapsulation (62.6%) of dibucaine (DBC) into liposomes. Light scattering and nanotracking analyses were used to characterize vesicle properties, such as, size, polydispersity, zeta potentials, and number. In vitro kinetic experiments revealed the sustained release of DBC (50% in 7 h) from the liposomes. In addition, in vitro (3T3 cells in culture) and in vivo (zebrafish) toxicity assays revealed that ionic-gradient liposomes were able to reduce DBC cyto/cardiotoxicity and morphological changes in zebrafish larvae. Moreover, the anesthesia time attained after infiltrative administration in mice was longer with encapsulated DBC (27 h) than that with free DBC (11 h), at 320 μM (0.012%), confirming it as a promising long-acting liposome formulation for parenteral drug administration of DBC. 相似文献